Deborah Knobelman - Oct 3, 2022 Form 4 Insider Report for Senti Biosciences, Inc. (SNTI)

Role
Chief Financial Officer
Signature
/s/ Mike Rhee, attorney-in-fact
Stock symbol
SNTI
Transactions as of
Oct 3, 2022
Transactions value $
$0
Form type
4
Date filed
10/4/2022, 04:47 PM
Previous filing
Jun 15, 2022
Next filing
Feb 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNTI Common Stock Award $0 +30K $0.00 30K Oct 3, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNTI Stock Option (Right to Buy) Award $0 +240K $0.00 240K Oct 3, 2022 Common Stock 240K $2.50 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares reported in this transaction represent restricted stock units ("RSUs") issued under the Senti Biosciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. All of the shares underlying the award will vest on September 20, 2024, subject to the reporting person's continued service through the applicable vesting date.
F2 25% of the shares underlying this option vest on September 20, 2023 and the remainder vest in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued service through the applicable vesting date.